FEMSA
FMX
117.11
+0.13
+0.11%
FEMSA
US · FMX
#549 by market cap
Listed 1970
117.11
+0.13
+0.11%
Live - 5344 symbols - heartbeat 76s ago
· 2026-10-07 19:54
After-hours
117.11
0.00%
- Market cap
- 39.97B
- P/E (TTM)i
- 24.87
- P/Bi
- 2.39
- EPSi
- 3.11
- Div yieldi
- 5.94%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on FMX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.01, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.60% YoY
Margins
- Gross margin
- 40.62%
- Operating margin
- 8.58%
- Net margin
- 2.31%
Key ratios & quality
- Enterprise valuei
- 74.80B
- Altman Z-Scorei
- 2.01
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 469.74B | 506.71B | 492.97B | 505.46B | 597.01B | 702.69B | 781.59B | 840.95B |
| Gross profit | 175.17B | 191.48B | 189.65B | 206.18B | 241.52B | 279.51B | 321.51B | 341.58B |
| Selling & admin expenses | 132.04B | 141.82B | 146.39B | 152.10B | 177.43B | 221.04B | 251.09B | 268.70B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 42.63B | 49.10B | 39.22B | 53.85B | 63.63B | 57.36B | 70.41B | 72.16B |
| Pretax profit | 33.63B | 32.30B | 19.31B | 42.99B | 46.50B | 57.82B | 66.55B | 52.84B |
| Tax | 10.17B | 10.48B | 14.82B | 13.57B | 13.28B | 12.97B | 25.43B | 19.86B |
| Net profit | 33.08B | 28.05B | 3.76B | 37.68B | 34.74B | 76.68B | 40.24B | 33.05B |
| Basic EPS | 60 | 52 | -5 | 71 | 60 | 164 | 68 | 50 |
| Diluted EPS | 60.00 | 51.50 | -5.00 | 71.00 | 59.50 | 164.00 | 67.00 | 49.50 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 195.82B | 211.36B | 214.64B | 220.10B | 207.78B | 231.00B |
| Gross profit | 78.92B | 85.92B | 85.71B | 91.43B | 84.09B | 92.61B |
| Selling & admin expenses | 65.39B | 68.41B | 67.82B | 67.40B | 69.63B | 73.92B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 13.56B | 17.83B | 18.13B | 22.71B | 14.31B | 19.11B |
| Pretax profit | 11.32B | 10.84B | 12.92B | 17.81B | 21.40B | 14.09B |
| Tax | 4.78B | 4.34B | 3.79B | 7.01B | 3.66B | 4.91B |
| Net profit | 8.94B | 5.59B | 5.84B | 12.69B | 17.64B | 9.22B |
| Basic EPS | 17 | 8 | 7 | 25 | 43 | 16 |
| Diluted EPS | 16.73 | 7.83 | 6.99 | 24.84 | 43.20 | 16.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 177.61B | 172.58B | 201.27B | 230.72B | 226.45B | 356.16B | 342.31B | 283.12B |
| Cash & ST investments | 92.97B | 77.93B | 108.29B | 121.82B | 83.49B | 191.84B | 183.05B | 128.02B |
| Inventory | 35.69B | 41.02B | 44.03B | 50.90B | 62.22B | 58.22B | 67.46B | 69.45B |
| Total assets | 576.38B | 637.54B | 684.85B | 737.50B | 798.82B | 805.86B | 851.54B | 795.88B |
| Total current liabilities | 101.46B | 136.53B | 118.41B | 136.72B | 176.92B | 182.38B | 202.93B | 210.01B |
| Short-term debt | 13.67B | 23.59B | 15.57B | 11.95B | 30.44B | 20.69B | 20.52B | 35.86B |
| Long-term debt | 114.99B | 101.75B | 179.86B | 185.95B | 173.40B | 128.37B | 141.48B | 126.99B |
| Total liabilities | 240,839,000,000.00 | 311,790,000,000.00 | 377,661,000,000.00 | 402,383,000,000.00 | 461,014,000,000.00 | 427,487,000,000.00 | 470,405,000,000.00 | 466,525,000,000.00 |
| Total equity | 335.54B | 325.75B | 307.19B | 335.12B | 337.80B | 378.37B | 381.13B | 329.35B |
| Retained earnings | 217.80B | 229.79B | 217.43B | 238.31B | 251.19B | 304.65B | 306.40B | 278.83B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 333.56B | 323.26B | 296.42B | 283.12B | 269.32B | 272.11B |
| Cash & ST investments | 169.72B | 162.31B | 148.94B | 128.02B | 114.58B | 116.55B |
| Inventory | 66.55B | 66.61B | 63.49B | 69.45B | 67.66B | 67.55B |
| Total assets | 855.88B | 831.04B | 807.96B | 795.88B | 801.33B | 802.58B |
| Total current liabilities | 203.39B | 241.37B | 220.97B | 210.01B | 232.97B | 239.47B |
| Short-term debt | 34.61B | 34.81B | 32.32B | 35.86B | 22.61B | 30.38B |
| Long-term debt | 131.74B | 136.22B | 130.82B | 126.99B | 137.33B | 124.83B |
| Total liabilities | 464,107,000,000.00 | 505,992,000,000.00 | 480,522,000,000.00 | 466,525,000,000.00 | 507,031,000,000.00 | 501,647,000,000.00 |
| Total equity | 391.78B | 325.05B | 327.44B | 329.35B | 294.30B | 300.94B |
| Retained earnings | -- | -- | -- | 278.83B | -- | -- |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 48.89B | 61.64B | 53.17B | 73.09B | 72.58B | 49.68B | 71.51B | 71.08B |
| Depreciation & amortization | 17.24B | 25.81B | 28.05B | 27.99B | 30.53B | 34.02B | 39.31B | 44.14B |
| Free cash flow | 25.52B | 36.52B | 33.03B | 53.61B | 41.10B | 11.56B | 24.20B | 29.03B |
| Dividends paid | -12.93B | -13.63B | -15.87B | -13.40B | -17.51B | -18.80B | -25.08B | -49.93B |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -20.31B | -12.36B |
| Ending cash balance | 62.05B | 65.56B | 107.62B | 97.41B | 83.44B | 165.11B | 139.83B | 107.98B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.46 | 8.13 | -0.79 | 11.39 | 9.10 | 23.19 | 8.89 | 7.16 |
| ROA %i | 4.12 | 3.41 | -0.29 | 4.01 | 3.11 | 8.19 | 3.23 | 2.36 |
| ROIC %i | 6.97 | 6.45 | 1.69 | 7.40 | 5.74 | 12.06 | 5.53 | 4.95 |
| 5-year avg ROE %i | 11.50 | 11.10 | 8.93 | 9.06 | 7.35 | 10.21 | 10.36 | 11.95 |
| EBIT margin %i | 8.60 | 8.59 | 7.14 | 10.01 | 8.26 | 10.67 | 10.76 | 8.47 |
| FCF / sales %i | 5.12 | 7.21 | 6.70 | 9.49 | 5.96 | 1.65 | 3.10 | 3.45 |
| Current ratioi | 1.75 | 1.26 | 1.70 | 1.69 | 1.28 | 1.95 | 1.69 | 1.35 |
| Quick ratioi | 1.36 | 0.93 | 1.30 | 1.27 | 0.84 | 1.47 | 1.24 | 0.99 |
| Debt / assetsi | 22.32 | 27.08 | 36.06 | 34.30 | 35.69 | 28.90 | 30.10 | 32.36 |
| LT debt / equityi | 44.73 | 59.15 | 97.33 | 91.77 | 96.96 | 69.84 | 79.25 | 90.49 |
| Interest coveragei | 5.98 | 3.88 | 2.22 | 3.85 | 3.99 | 4.36 | 4.79 | 3.87 |
| Revenue CAGR (3Y) %i | 14.66 | 8.25 | 3.87 | 2.47 | 5.62 | 12.54 | 15.64 | 12.10 |
| Net income CAGR (3Y) %i | 8.46 | -0.70 | -- | 8.10 | 4.92 | -- | -2.10 | -6.68 |
| FCF CAGR (3Y) %i | 11.74 | 8.31 | 23.24 | 28.08 | 4.03 | -29.53 | -23.29 | -10.94 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 10.79 | 7.44 | 5.96 | 7.16 | 10.98 | 13.66 |
| ROA %i | 3.79 | 2.40 | 1.97 | 2.36 | 3.43 | 3.83 |
| ROIC %i | 6.65 | 4.97 | 4.38 | 4.95 | 7.11 | 8.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 11.04 | 9.26 | 8.46 | 8.47 | 9.57 | 9.75 |
| FCF / sales %i | -- | -- | -- | 3.45 | -- | -- |
| Current ratioi | 1.64 | 1.34 | 1.34 | 1.35 | 1.16 | 1.14 |
| Quick ratioi | 1.04 | 0.85 | 0.88 | 0.99 | 0.68 | 0.68 |
| Debt / assetsi | 30.57 | 31.95 | 31.87 | 32.36 | 32.17 | 31.52 |
| LT debt / equityi | 73.67 | 95.55 | 92.37 | 90.49 | 112.01 | 102.80 |
| Interest coveragei | 4.89 | 4.24 | 3.75 | 3.87 | 4.36 | 4.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- OXXO Mexico is the largest reported line at 37.96% of revenue, across 5 reported segments.
- No single line clears half of revenue; Coca-Cola Fomento Economico Mexicano, S.A.B. de C.V. and subsidiaries (FEMSA) is next at 33.41%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
OXXO Mexico37.96%
Coca-Cola Fomento Economico Mexicano, S.A.B. de C.V. and subsidiaries (FEMSA)33.41%
Americas & Mobility12.51%
Health9.78%
Europe6.34%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.